Publications by authors named "Alan Sandler"

100Publications

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

N Engl J Med 2020 10;383(14):1328-1339

From the Yale School of Medicine, New Haven, CT (R.S.H.); Weill Cornell Medical Center, New York (G.G.); the European Institute of Oncology, IRCCS, Milan (F.M.); Asklepios Lung Clinic, Munich-Gauting, Germany (N.R.); University Hospital Limoges, Limoges, France (A.V.); Centro de Pesquisa Clínica, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil (C.H.B.); Nagoya University Graduate School of Medicine, Aichi, Japan (M. Morise); Vall d'Hebron University Hospital, Barcelona (E.F.); Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia (Z.A.); Prince of Songkla University-Hat Yai, Songkhla, Thailand (S.G.); Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey (M.O.); Genentech, South San Francisco, CA (W.Z., A.S., I.E., K.K., Y.D., H.K., X.W., M. McCleland, S.M.); the Medical University of Gdańsk, Gdansk, Poland (J.J.); and the Sarah Cannon Research Institute at Tennessee Oncology, Nashville (D.R.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1917346DOI Listing
October 2020

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

Cancer Treat Rev 2020 Jun 26;86:102017. Epub 2020 Mar 26.

Aix-Marseille University, Assistance Publique-Hopitaux de Marseille, Centre Hospitalo-Universitaire Timone, Service de Neuro-Oncologie, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102017DOI Listing
June 2020

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

N Engl J Med 2018 12 25;379(23):2220-2229. Epub 2018 Sep 25.

From Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute-Tennessee Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock (A. Szczęsna), and Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) - both in Poland; Thomayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical Care Medicine (M.J.H.) and the 2nd Department of Respiratory and Critical Care Medicine (F.H.), Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology-Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Vienna; Semmelweis Egyetem ÁOK, Pulmonológiai Klinika, Budapest, Hungary (G.L.); the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.), and F. Hoffmann-La Roche, Shanghai (J.L.) - both in China; Genentech, South San Francisco, CA (S.L., D.S.S., B.D., A.L.-C., F.K., W.L., A. Sandler); and Georgetown University, Washington DC (S.V.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809064
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809064DOI Listing
December 2018

Recent progress in therapeutic antibodies for cancer immunotherapy.

Curr Opin Chem Biol 2018 06 7;44:56-65. Epub 2018 Jun 7.

Genentech, 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13675931183005
Publisher Site
http://dx.doi.org/10.1016/j.cbpa.2018.05.006DOI Listing
June 2018

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

N Engl J Med 2018 Jun 4;378(24):2288-2301. Epub 2018 Jun 4.

From the Florida Hospital Cancer Institute, Orlando (M.A.S.); Rocky Mountain Cancer Centers, Denver (R.M.J.); US Oncology, Houston (R.M.J.); Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy (F.C.); Instituto Nacional del Torax, Santiago, Chile (F.O.); Moscow City Oncology Hospital, Moscow (D.S.); National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan (N.N.); Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain (D.R.-A.); Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble (D.M.-S.), and Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.) - both in France; New England Cancer Specialists, Scarborough, ME (C.A.T.); Allegheny Health Network Cancer Institute, Pittsburgh (G.F.); Genentech, South San Francisco, CA (C.K., A.L., S.C., Y.D., Y.S., M.K., A.L.-C., A.S.); and Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany (M.R.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1716948
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1716948DOI Listing
June 2018

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

J Clin Oncol 2017 Aug 13;35(24):2781-2789. Epub 2017 Jun 13.

Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne; Martin Früh, Kantonsspital St Gallen, St Gallen, Switzerland; Scott Gettinger, Yale Cancer Center, New Haven, CT; Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, TN; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Daniel Christoph, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; Chee Keong Toh, National Cancer Centre, Singapore, Singapore; Naiyer A. Rizvi and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Weill Cornell Medical College, New York, NY; Enric Carcereny Costa, Catalan Institute of Oncology Badalona, Badalona; Luis Paz-Ares, Hospital Universitario Doce de Octubre & IIS i+12, CNIO, Ciberonc and Universidad Complutense, Madrid; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Jyoti D. Patel, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; Marianna Koczywas, City of Hope, Duarte; Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, and Alan Sandler, Genentech, South San Francisco, CA; Cheryl Ho, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia; Jeffrey Rothenstein, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa; Frances A. Shepherd, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada; Michel van den Heuvel, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; and Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562171PMC
August 2017

Prospects and progress of atezolizumab in non-small cell lung cancer.

Expert Opin Biol Ther 2017 06 28;17(6):781-789. Epub 2017 Mar 28.

e US Oncology Thoracic Oncology Program , Virginia Cancer Specialists , Fairfax , VA 22031.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2017.1309389DOI Listing
June 2017

Lung Cancer Survival Among Chinese Americans, 2000 to 2010.

J Glob Oncol 2016 Feb 20;2(1):30-38. Epub 2016 Jan 20.

, , , and , Cancer Prevention Institute of California, Fremont; and , Stanford School of Medicine; , , , , and , Stanford Cancer Institute, Stanford; and , , and , Genentech, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.2015.000539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497738PMC
February 2016

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Aug 13;33(24):2667-74. Epub 2015 Jul 13.

Giorgio Scagliotti and Silvia Novello, University of Turin, Orbassano, Torino; Adolfo Favaretto, Istituto Oncologico Veneto, Padova; Armando Santoro, Istituto Clinico Humanitas, Milan, Italy; Joachim von Pawel, Asklepios-Fachkliniken München-Gauting, Munich, Germany; Rodryg Ramlau, Poznań University of Medical Sciences, Poznań, Poland; Fabrice Barlesi, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Wallace Akerley, Huntsman Cancer Institute, Salt Lake City, UT; Sergey Orlov, St Petersburg State Medical University, St Petersburg, Russian Federation; David Spigel, Clinical Locations, Nashville, TN; Vera Hirsh, McGill University Health Centre, Montreal, Quebec; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Lecia V. Sequist, Massachusetts General Hospital, Boston; Jeffrey S. Ross, Foundation Medicine, Cambridge; Brian Schwartz, ArQule, Woburn, MA; Alan Sandler, Genentech, San Francisco, CA; and Qiang Wang, Reinhard von Roemeling, and Dale Shuster, Daiichi Sankyo, Edison, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.7317DOI Listing
August 2015

Incidence trends of lung cancer by immigration status among Chinese Americans.

Cancer Epidemiol Biomarkers Prev 2015 Aug 19;24(8):1157-64. Epub 2015 May 19.

Cancer Prevention Institute of California, Fremont, California. Department of Health Research and Policy (Epidemiology), Stanford School of Medicine, Stanford, California. Stanford Cancer Institute, Palo Alto, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-15-0123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746176PMC
August 2015

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

J Clin Oncol 2015 Mar 9;33(9):1000-7. Epub 2015 Feb 9.

Ariel Lopez-Chavez, Anish Thomas, Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan Kelly, Corey Allan Carter, Udayan Guha, Keith Killian, Christopher C. Lau, Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer, David J. Liewehr, Seth M. Steinberg, Arlene Berman, Eva Szabo, Yisong Wang, and Giuseppe Giaccone, National Cancer Institute; Austin Doyle, Cancer Therapy Evaluation Program, Bethesda, MD; Ariel Lopez-Chavez, Christopher L. Corless, Alan Sandler, Carol Beadling, and Andrea Warrick, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; Ariel Lopez-Chavez, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yisong Wang and Giuseppe Giaccone, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/02/03/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.2007
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.2007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356709PMC
March 2015

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.

Am J Clin Oncol 2016 10;39(5):441-7

*Abramson Cancer Center, University of Pennsylvania, Philadelphia †University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA ‡Feinberg School of Medicine, Northwestern University, Chicago, IL §Genentech Inc., South San Francisco, CA ∥Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX ¶Winship Cancer Institute of Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016219PMC
October 2016

Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer.

J Thorac Oncol 2014 Apr;9(4):559-62

*Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee; †Department of Biostatistics, Center for Quantitative Science, Vanderbilt University Medical Center, Nashville, Tennessee; ‡South Carolina Oncology Associates, Columbia, South Carolina; §Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, OHSU Knight Cancer Institute, Portland, Oregon; ‖Department of Medicine, Division of Medical Oncology, The Ohio State University Medical Center, Arthur G. James Cancer Hospital, Columbus, Ohio; ¶Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and #Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000079DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990869PMC
April 2014

A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.

J Thorac Oncol 2013 Dec;8(12):1510-8

*Department of Medicine, Duke University Medical Center, Durham, North Carolina; †Hematology Oncology Associates, Port St. Lucie, Florida; ‡Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana; §Oregon Health and Science University, Portland, Oregon; ‖Illinois CancerCare, Peoria, Illinois; ¶Departments of Global Biostatistical Science, Oncology Research, and Global Safety, Amgen Inc., Thousand Oaks, California; and #Division of Hematology and Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a7d1daDOI Listing
December 2013

EGFR tyrosine kinase inhibitors: difference in efficacy and resistance.

Curr Oncol Rep 2013 Aug;15(4):396-404

Oregon Health and Science University, 3181 SW Sam Jackson Park Road, MC: L586, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11912-013-0323
Web Search
http://link.springer.com/10.1007/s11912-013-0323-7
Publisher Site
http://dx.doi.org/10.1007/s11912-013-0323-7DOI Listing
August 2013

The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.

Oncologist 2013 23;18(2):115-22. Epub 2013 Jan 23.

Oregon Health & Science Center, 3181 SW Sam Jackson Park Road, MC: L586, Portland, Oregon 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0262DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579594PMC
December 2013

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.

Lung Cancer 2012 Oct 9;78(1):1-7. Epub 2012 Aug 9.

Hematology/Oncology Division, Oregon Health Sciences University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2012.07.004DOI Listing
October 2012

Systemic issues in small cell lung cancer.

Curr Probl Cancer 2012 May-Jun;36(3):131-55

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2012.03.004DOI Listing
August 2012

Identifying barriers associated with enrollment of patients with lung cancer into clinical trials.

Clin Lung Cancer 2013 Jan 15;14(1):14-8. Epub 2012 May 15.

Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2012.03.008DOI Listing
January 2013

Beyond bevacizumab: antiangiogenic agents.

Clin Lung Cancer 2012 Sep 31;13(5):326-33. Epub 2012 Jan 31.

Providence Oncology and Hematology Care Clinic-Southeast, Clackamas, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2011.12.001DOI Listing
September 2012

A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.

Clin Lung Cancer 2011 May 27;12(3):161-5. Epub 2011 Apr 27.

Vanderbilt Ingram Cancer Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2011.03.013DOI Listing
May 2011

Phase III clinical trial development: a process of chutes and ladders.

Clin Cancer Res 2010 Nov 9;16(22):5381-9. Epub 2010 Nov 9.

Knight Cancer Institute, Center for Management Research in Healthcare, Division of Management, School of Medicine, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058405PMC
November 2010

Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer.

J Thorac Oncol 2010 Sep;5(9):1416-23

Division of Hematology/Oncology, Department of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3181da36f4DOI Listing
September 2010

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

J Clin Oncol 2010 Feb 19;28(6):949-54. Epub 2010 Jan 19.

Department of Biostatistics and Computational Biology, CLSB 11007, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.25.4482
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.25.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834434PMC
February 2010

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.

Cancer Chemother Pharmacol 2010 Sep 31;66(4):669-80. Epub 2009 Dec 31.

Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-1209-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904454PMC
September 2010

Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.

Clin Cancer Res 2009 Aug 11;15(16):5040-8. Epub 2009 Aug 11.

Vanderbilt Ingram Cancer Centre, Division of Hematology/Oncology, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-09-0520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528182PMC
August 2009

Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.

Clin Lung Cancer 2009 Mar;10 Suppl 1:S7-16

Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2009.s.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528174PMC
March 2009

Angiogenesis in the treatment of non-small cell lung cancer.

Proc Am Thorac Soc 2009 Apr;6(2):206-17

Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN 32323-6307, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1513/pats.200807-066LCDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820832PMC
April 2009

Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.

Clin Lung Cancer 2009 Jan;10(1):20-7

Section of Thoracic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2009.n.003DOI Listing
January 2009

A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.

Clin Cancer Res 2009 Mar 10;15(6):2158-65. Epub 2009 Mar 10.

Vanderbilt University Medical Center, Nashville, Tennessee and University of Texas Southwestern Medical Center, Dallas, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-0629DOI Listing
March 2009

Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.

J Clin Oncol 2009 Apr 2;27(11):1761-6. Epub 2009 Mar 2.

Center for Management Research in Healthcare, Vanderbilt University, Nashville, TN 37235-1518, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.9133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668703PMC
April 2009

Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.

Oncologist 2008 Nov 8;13(11):1166-76. Epub 2008 Nov 8.

The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2008-0108DOI Listing
November 2008

A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.

Invest New Drugs 2009 Feb 11;27(1):75-81. Epub 2008 Jul 11.

University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL, 60637-1460, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-008-9160-1DOI Listing
February 2009

Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group.

Clin Cancer Res 2008 Jun;14(11):3427-33

Owen Graduate School of Management and Engineering Management Program, School of Engineering, Vanderbilt University, 401 21st Avenue South, Nashville, TN 37203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-5060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723742PMC
June 2008

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

J Clin Oncol 2008 Mar;26(9):1472-8

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.13.0062DOI Listing
March 2008

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).

Chest 2007 Sep;132(3 Suppl):277S-289S

Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB# 7305, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1378/chest.07-1381DOI Listing
September 2007

Inhibition of angiogenesis in the treatment of non-small cell lung cancer.

Cancer Sci 2007 Dec 24;98(12):1825-30. Epub 2007 Sep 24.

Vanderbilt-Ingram Cancer Center, Vanderbilt University, Department of Medicine, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37272-6307, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1349-7006.2007.00620.xDOI Listing
December 2007

Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer.

Cancer Epidemiol Biomarkers Prev 2007 Sep;16(9):1845-51

Department of Radiation Oncology, Vanderbilt University, 1301 Medical Center Drive, B-902 The Vanderbilt Clinic, Nashville, TN 37232-5671, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-07-0146DOI Listing
September 2007

Bevacizumab in non small cell lung cancer.

Authors:
Alan Sandler

Clin Cancer Res 2007 Aug;13(15 Pt 2):s4613-6

Thoracic Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232-6307, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0647DOI Listing
August 2007

Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.

Clin Cancer Res 2007 Aug;13(15 Pt 2):s4583-8

Division of Hematology/Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA. .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0716DOI Listing
August 2007

Lung cancer adjuvant therapy.

Cancer J 2007 May-Jun;13(3):210-6

Department of Medicine, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00130404-200705000-000
Publisher Site
http://dx.doi.org/10.1097/PPO.0b013e318074d8f6DOI Listing
January 2008

The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer.

J Thorac Oncol 2007 May;2(5):377-83

Division of Hematology and Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.JTO.0000268669.64625.bbDOI Listing
May 2007

Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594.

J Thorac Oncol 2006 Jun;1(5):441-6

Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305-5826, USA.

View Article

Download full-text PDF

Source
June 2006

Chemotherapy and antiangiogenic agents in non-small-cell lung cancer.

Clin Lung Cancer 2007 Feb;8 Suppl 2:S68-73

Department of Medicine, University of Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clc.2007.s.004DOI Listing
February 2007

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.

Cancer Res 2006 Dec;66(23):11409-15

Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-5671, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-2414DOI Listing
December 2006

Angiogenesis inhibition in the treatment of lung cancer.

Clin Adv Hematol Oncol 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2

University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
November 2006

Protecting human subjects in the NIH's Intramural Research Program: a draft instrument to evaluate convened meetings of its IRBs.

IRB 2006 May-Jun;28(3):7-10

Office of Human Subjects Research, Office of the Director, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
October 2006

Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.

J Clin Oncol 2006 Oct;24(28):4545-52

Center for Management Research in Healthcare, Vanderbilt University, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.05.0104DOI Listing
October 2006

Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.

Clin Cancer Res 2006 Jul;12(14 Pt 2):4421s-4425s

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232-6307, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0796DOI Listing
July 2006

Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.

Oncologist 2006 Jun;11(6):655-65

Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.11-6-655DOI Listing
June 2006